Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kathleen M Moore

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Diseases of Aquatic Organisms|December 3, 2011
Lethal entanglement in baleen whalesRachel M Cassoff, Kathleen M Moore, William A McLellan, et al.
Biomarker Insights|April 4, 2022
Circulating Tumor Cell-Free DNA Genes as Prognostic Gene Signature for Platinum Resistant Ovarian Cancer DiagnosisCamille C Gunderson, Rangasudhagar Radhakrishnan, Rohini Gomathinayagam, et al.
The Journal of Laboratory and Clinical Medicine|November 29, 2005
Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need?Theodore E Warkentin, Jo-Ann I Sheppard, Jane C Moore, et al.
Gynecologic Oncology|May 22, 2016
Primary and acquired platinum-resistance among women with high grade serous ovarian cancerKatrina Slaughter, Laura L Holman, Eric L Thomas, et al.
JCO Clinical Cancer Informatics|January 6, 2023
Historic Clinical Trial External Control Arm Provides Actionable GEN-1 Efficacy Estimate Before a Randomized TrialXiang Yin, Ruthanna Davi, Elizabeth B Lamont, et al.
Gynecologic Oncology|December 4, 2021
Breast cancer surveillance following ovarian cancer in BRCA mutation carriersCatherine S John, Abigail Fong, Rodrigo Alban, et al.
The American Surgeon|October 27, 2020
Breast Cancer Surveillance Following Ovarian Cancer in BRCA Mutation CarriersAbigail Fong, Ilana Cass, Catherine John, et al.
Investigational New Drugs|March 12, 2017
Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancersJennifer R Diamond, Barbara Goff, Martin D Forster, et al.
Gynecologic Oncology|July 2, 2019
Comprehensive genomic profiling of recurrent endometrial cancer: Implications for selection of systemic therapyEmily N Prendergast, Laura L Holman, Annie Y Liu, et al.
Gynecologic Oncology|May 22, 2017
Quality of life among long-term survivors of advanced stage ovarian cancer: A cross-sectional approachSusan K Lutgendorf, Eileen Shinn, Jeanne Carter, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Diseases of Aquatic Organisms|December 3, 2011
Lethal entanglement in baleen whalesRachel M Cassoff, Kathleen M Moore, William A McLellan, et al.
Biomarker Insights|April 4, 2022
Circulating Tumor Cell-Free DNA Genes as Prognostic Gene Signature for Platinum Resistant Ovarian Cancer DiagnosisCamille C Gunderson, Rangasudhagar Radhakrishnan, Rohini Gomathinayagam, et al.
The Journal of Laboratory and Clinical Medicine|November 29, 2005
Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need?Theodore E Warkentin, Jo-Ann I Sheppard, Jane C Moore, et al.
Gynecologic Oncology|May 22, 2016
Primary and acquired platinum-resistance among women with high grade serous ovarian cancerKatrina Slaughter, Laura L Holman, Eric L Thomas, et al.
JCO Clinical Cancer Informatics|January 6, 2023
Historic Clinical Trial External Control Arm Provides Actionable GEN-1 Efficacy Estimate Before a Randomized TrialXiang Yin, Ruthanna Davi, Elizabeth B Lamont, et al.
Gynecologic Oncology|December 4, 2021
Breast cancer surveillance following ovarian cancer in BRCA mutation carriersCatherine S John, Abigail Fong, Rodrigo Alban, et al.
The American Surgeon|October 27, 2020
Breast Cancer Surveillance Following Ovarian Cancer in BRCA Mutation CarriersAbigail Fong, Ilana Cass, Catherine John, et al.
Investigational New Drugs|March 12, 2017
Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancersJennifer R Diamond, Barbara Goff, Martin D Forster, et al.
Gynecologic Oncology|July 2, 2019
Comprehensive genomic profiling of recurrent endometrial cancer: Implications for selection of systemic therapyEmily N Prendergast, Laura L Holman, Annie Y Liu, et al.
Gynecologic Oncology|May 22, 2017
Quality of life among long-term survivors of advanced stage ovarian cancer: A cross-sectional approachSusan K Lutgendorf, Eileen Shinn, Jeanne Carter, et al.
Pageof 2